This trade activity should not be overlooked: Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock fell -1.55% on Monday to $39.35 against a previous-day closing price of $39.97. With 0.6 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.92 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $40.40 whereas the lowest price it dropped to was $38.31. The 52-week range on RARE shows that it touched its highest point at $54.98 and its lowest point at $31.52 during that stretch. It currently has a 1-year price target of $90.00. Beta for the stock currently stands at 0.74.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RARE was up-trending over the past week, with a rise of 11.44%, but this was up by 18.81% over a month. Three-month performance surged to 9.06% while six-month performance fell -22.40%. The stock gained 12.04% in the past year, while it has lost -15.07% so far this year. A look at the trailing 12-month EPS for RARE yields -8.98 with Next year EPS estimates of -6.35. For the next quarter, that number is -1.70. This implies an EPS growth rate of 17.13% for this year and 24.32% for next year. EPS is expected to grow by 8.90% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -7.28%.

Float and Shares Shorts:

At present, 82.11 million RARE shares are outstanding with a float of 78.38 million shares on hand for trading. On Oct 30, 2023, short shares totaled 4.16 million, which was 5.07% higher than short shares on Sep 28, 2023. In addition to Dr. Emil D. Kakkis M.D., Ph.D. as the firm’s Founder, President, CEO & Director, Mr. John Richard Pinion II serves as its Chief Quality Operations Officer & Executive VP of Translational Sciences.

Institutional Ownership:

Other institutions hold 47.99% of RARE, in contrast to 40.50% held by mutual funds. Shares owned by individuals account for 10.29%. As the largest shareholder in RARE with 8.68% of the stake, The Vanguard Group, Inc. holds 7,129,999 shares worth 7,129,999. A second-largest stockholder of RARE, RTW Investments LP, holds 5,405,089 shares, controlling over 6.58% of the firm’s shares. Wellington Management Co. LLP is the third largest shareholder in RARE, holding 5,195,880 shares or 6.33% stake. With a 2.89% stake in RARE, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 2,370,958 shares are owned by the mutual fund manager. The Vanguard Explorer Fund, which owns about 2.38% of RARE stock, is the second-largest Mutual Fund holder. It holds 1,957,121 shares valued at 69.28 million. Vanguard Small Cap Index Fund holds 2.38% of the stake in RARE, owning 1,955,552 shares worth 69.23 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RARE since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RARE analysts setting a high price target of $140.00 and a low target of $43.00, the average target price over the next 12 months is $90.00. Based on these targets, RARE could surge 255.78% to reach the target high and rise by 9.28% to reach the target low. Reaching the average price target will result in a growth of 128.72% from current levels.

Summary of Insider Activity:

Insiders traded RARE stock several times over the past three months with 1 Buys and 5 Sells. In these transactions, 2,000 shares were bought while 9,133 shares were sold. The number of buy transactions has increased to 24 while that of sell transactions has risen to 28 over the past year. The total number of shares bought during that period was 225,162 while 96,043 shares were sold.